Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Enicepatide · 5 trials · 6 indications
| Arm | Type | Description |
|---|---|---|
| Enicepatide Dose 1 | EXPERIMENTAL | Participants will receive enicepatide Dose 1. |
| Enicepatide Dose 2 | EXPERIMENTAL | Participants will receive enicepatide Dose 2. |
| Enicepatide Dose 3 | EXPERIMENTAL | Participants will receive enicepatide Dose 3. |
| Placebo | PLACEBO_COMPARATOR | Participants will receive matching placebo. |
| Arm 1: Placebo | PLACEBO_COMPARATOR | - |
| Arm 2: Enicepatide Dosing Regimen 1 | EXPERIMENTAL | - |
| Arm 3: Enicepatide Dosing Regimen 2 | EXPERIMENTAL | - |
| Arm 4: Enicepatide Dosing Regimen 3 | EXPERIMENTAL | - |
| Arm 2: Enicepatide Dose Level 1 (Low) | EXPERIMENTAL | Enicepatide Dose Level 1 administered SC once weekly. |
| Arm 3: Enicepatide Dose Level 2 | EXPERIMENTAL | Enicepatide Dose Level 2 administered SC once weekly. |
| Arm 4: Enicepatide Dose Level 3 | EXPERIMENTAL | Enicepatide Dose Level 3 administered SC once weekly. |
| Arm 5: Enicepatide Dose Level 4 | EXPERIMENTAL | Enicepatide Dose Level 4 administered SC once weekly. |
| Arm 6: Enicepatide Dose Level 5 (High) | EXPERIMENTAL | Enicepatide Dose Level 5 administered SC once weekly. |
| Name | Type | Description |
|---|---|---|
| Enicepatide | COMBINATION_PRODUCT | Participants will receive enicepatide via subcutaneous (SC) injection as per the schedule in the protocol. |
| Placebo | COMBINATION_PRODUCT | Participants will receive matching placebo via SC injection as per the schedule in the protocol. |
Inclusion Criteria: * Body mass index (BMI) ≥24.0 kilograms per meter squared (kg/m\^2) for participants with type 2 diabetes mellitus (T2DM) * BMI ≥28.0 kg/m\^2 or BMI ≥24.0 and \<28.0 kg/m\^2 and diagnosed with at least one weight-related comorbidity (prediabetes, hypertension, dyslipidemia, fatt...
Top 20 of 32 competitors
Enicepatide is an investigational small molecule being developed for obesity or overweight, including in people with weight-related comorbidities or type 2 diabetes. It is being studied in participants with obesity or overweight, with or without type 2 diabetes, and is not yet approved for any use.
Enicepatide is a peptide-based small molecule, classified under the -tide (peptide) target class. Its specific molecular target is not disclosed in the available information. It is being studied for its effects on weight in people with obesity or overweight.
Enicepatide is being developed by Roche Holding AG, traded on the OTC market under the ticker RHHBY. The company is conducting clinical trials to evaluate the drug's effects in participants with obesity or overweight, with or without type 2 diabetes.
Enicepatide is in Phase 3 clinical development. It has completed a Phase 2 trial and is currently being evaluated in multiple Phase 3 trials. It is an investigational drug and has not been approved by regulatory authorities.
Enicepatide is being studied in several Phase 3 trials, including NCT07351045 in participants with obesity or overweight without type 2 diabetes, NCT07351058 in those with type 2 diabetes, and NCT07670416 in China. A Phase 2 trial, NCT06525935, has been completed.
Yes, Enicepatide is also known as CT-388, as indicated in the Phase 2 trial title. It is also referred to as RO7795068 in Phase 3 trial titles. These names refer to the same investigational drug being developed by Roche.